Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Biomark Diagnostics Inc. (OTC: BMKDF).

Full DD Report for BMKDF

You must become a subscriber to view this report.


Recent News from (OTC: BMKDF)

BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making
(via TheNewswire) Vancouver, British Columbia / TheNewswire / April 25, 2018 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Os...
Source: TheNewsWire
Date: April, 25 2018 09:00
BIOMARK's Health Canada Submission Update
(via TheNewswire) Vancouver, British Columbia / TheNewswire / February 21, 2018 - BioMark Diagnostics Inc . ("BioMark") (CSE: BUX, FSE: 20B , OTC MKTS: BMKDF ) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical tria...
Source: TheNewsWire
Date: February, 21 2018 09:00
Further Progress in BIOMARK's Clinical Trial and Regulatory Review
(via TheNewswire) Vancouver, British Columbia / TheNewswire / January 3 rd , 2018 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B , OTC MKTS: BMKDF ) is pleased to provide further progress on its clinical trial activities as previously reported on November 1 s...
Source: TheNewsWire
Date: January, 03 2018 09:00
Global Affairs Canada Supports BioMark's Trip to Japan
(via TheNewswire) Vancouver, British Columbia / TheNewswire / December 19, 2017 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B , OTC MKTS: BMKDF ) is proud to announce that the Canadian Government's established Going Global International (GGI) program has generously appr...
Source: TheNewsWire
Date: December, 19 2017 09:00
Dr. Ian Smith Joins Biomark's Board of Directors
(via TheNewswire) Vancouver, British Columbia / TheNewswire / December 5, 2017 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company. Rashid Ahmed, Pre...
Source: TheNewsWire
Date: December, 05 2017 09:00
BioMark's Clinical Trial and Research Update
BioMark’s Clinical Trial and Research Update Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide the latest clinical trial update. The company analyzed samples from th...
Source: FSCwire
Date: November, 01 2017 09:00
Biomark Announces Patent Granted in China
Biomark Announces Patent Granted in China Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS:BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMID...
Source: FSCwire
Date: October, 25 2017 09:00
BioMark Announces Appointment of Scientific and Medical Advisors
BioMark Announces Appointment of Scientific and Medical Advisors Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed four distinguished experts to it...
Source: FSCwire
Date: October, 02 2017 09:00
Biomark Announces Multiple Patents Issued
Biomark Announces Multiple Patents Issued Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS:BMKDF) is pleased to announce that its patent family titled “METHOD FOR ASSAYING NONSPERMINE/SPERMIDI...
Source: FSCwire
Date: September, 18 2017 09:00
Biomark Closes First Tranche of Over-Subscribed Private Placement Offering
Biomark Closes First Tranche of Over-Subscribed Private Placement Offering Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that furt...
Source: FSCwire
Date: June, 29 2017 09:00

 


About Biomark Diagnostics Inc. (OTC: BMKDF)

Logo for Biomark Diagnostics Inc. (OTC: BMKDF)

BioMark is developing proprietary, non invasive, and accurate cancer diagnostic solutions which can help detect cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

 

 

 

Current Management

  • Rashid Ahmed / CEO, President
  • Abbey Abdiye / CFO
  • Brian Kia Ming Cheng /
  • Bramhananad Ramjiawan /

Current Share Structure

  • Market Cap: $3,647,248 - 03/09/2018
  • Authorized: 54,436,543 - 01/16/2015
  • Issue and Outstanding: 54,436,543 - 02/08/2017

 


Recent Filings from (OTC: BMKDF)

Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: February, 27 2017
Interim Financial Report - Interim Financial Report
Filing Type: Interim Financial Report - Interim Financial ReportFiling Source: OTC Markets
Filing Date: February, 27 2017
Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: November, 29 2016
Interim Financial Report - Interim Financial Report
Filing Type: Interim Financial Report - Interim Financial ReportFiling Source: OTC Markets
Filing Date: November, 29 2016
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 28 2016
Management Discussion and Analysis - Management Discussion and Analysis - June 30, 2016
Filing Type: Management Discussion and Analysis - Management Discussion and Analysis - June 30, 2016Filing Source: OTC Markets
Filing Date: August, 30 2016
Interim Financial Report - Interim Financial Report - JUne 30, 2016
Filing Type: Interim Financial Report - Interim Financial Report - JUne 30, 2016Filing Source: OTC Markets
Filing Date: August, 30 2016
Management Discussion and Analysis - Biomark Diagnostics Inc. -Annual MD&A - March 31, 2016
Filing Type: Management Discussion and Analysis - Biomark Diagnostics Inc. -Annual MD&A - March 31, 2016Filing Source: OTC Markets
Filing Date: August, 16 2016
Annual Report - Biomark Diagnostics Inc. - Audited Annual FS - March 31, 2016
Filing Type: Annual Report - Biomark Diagnostics Inc. - Audited Annual FS - March 31, 2016Filing Source: OTC Markets
Filing Date: August, 16 2016
Interim Financial Report - Interim Financial Report
Filing Type: Interim Financial Report - Interim Financial ReportFiling Source: OTC Markets
Filing Date: February, 25 2016

 

 


Daily Technical Chart for (OTC: BMKDF)

Daily Technical Chart for (OTC: BMKDF)


Stay tuned for daily updates and more on (OTC: BMKDF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BMKDF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMKDF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of BMKDF and does not buy, sell, or trade any shares of BMKDF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/